ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AbbVie, Boehringer Ingelheim's IL-23 inhibitor Skyrizi gains US approval for plaque psoriasis firstwordpharma
April 25, 2019AbbVie announced that the FDA approved Skyrizi (risankizumab-rzaa) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. -
FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis drugs
April 25, 2019FDA Approves Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis. -
Skyrizi gets US approval for psoriasis pharmatimes
April 24, 2019AbbVie has announced the US Food and Drug Administration (FDA) approval of its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) for moderate to severe plaque psoriasis.
Pharma Sources Insight July 2025
